摘要
目的研究血小板源性生长因子受体α多肽(PDGFRA)基因突变在胸腺上皮性肿瘤(TETs)中的临床应用价值。方法采用Sanger测序法和免疫组化方法分别检测47例TETs中PDGFRA基因突变和蛋白表达。结果47例TETs中,发生PDGFRA基因突变16例,均发生在第18号外显子,突变率为34.04%(16/47);将B3型胸腺瘤与胸腺癌合并统计,其PDGFRA基因突变率为60%(9/15),显著高于其他类型胸腺瘤的阳性突变率21.86%(7/32),两组比较差异显著(P<0.05)。结论PDGFRA基因有可能成为TETs靶向治疗、预测进展、分子分型及预后的新分子标记物,为下一步机制的研究和指导临床用药提供新的理论基础。
Objective To study the clinical value of platelet derived growth factor receptor alpha(PDGFRA)gene mutation in thymic epithelial tumors(TETs).Methods Sanger sequencing and immunohistochemistry were used to detect PDGFRA gene mutation and protein expression in 47 TETs.Results Among the 47 cases of TETs,16 cases of PDGFRA gene mutation were detected in exon 18,and the mutation rate was 34.04%(16/47).The combination of B3 thymoma and thymic carcinoma was statistically significant.The mutation rate of PDGFRA gene was 60.00%(9/15);the positive rate of positive mutation was significantly higher than other types of thymoma 21.86%(7/32),and the difference was statistically significant(P=0.01).Conclusion PDGFRA gene may be a new molecular marker for TETs targeted therapy,prediction of progress,molecular typing and prognosis.It provides a new theoretical basis for further mechanism studies and clinical therapy guidance.
作者
徐国栋
张玉萍
张云香
马昊
候倩
葛莉
蔡晓珊
XU Guo-dong;ZHANG Yu-ping;ZHANG Yun-xiang;MA Hao;HOU Qian;GE Li;CAI Xiao-shan(Department of Pathology,Weifang People’s Hospital,Weifang261041,China;Department of Pathology,Weifang Second People’s Hospital,Weifang261041,China)
出处
《诊断病理学杂志》
2020年第4期245-249,共5页
Chinese Journal of Diagnostic Pathology
基金
山东省重点研发计划项目(2015GSF118168)
潍坊市科技发展计划项目(2018YX012)。
